Syntara (ASX:SNT) Other Long-Term Liabilities : A$0.08 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Syntara Other Long-Term Liabilities?

Syntara's other long-term liabilities for the quarter that ended in Dec. 2023 was A$0.08 Mil.

Syntara's quarterly other long-term liabilities declined from Dec. 2022 (A$6.36 Mil) to Jun. 2023 (A$6.32 Mil) and declined from Jun. 2023 (A$6.32 Mil) to Dec. 2023 (A$0.08 Mil).

Syntara's annual other long-term liabilities declined from Jun. 2021 (A$18.52 Mil) to Jun. 2022 (A$5.94 Mil) but then increased from Jun. 2022 (A$5.94 Mil) to Jun. 2023 (A$6.32 Mil).

Syntara Other Long-Term Liabilities Historical Data

The historical data trend for Syntara's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Other Long-Term Liabilities Chart

Syntara Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Other Long-Term Liabilities

Get a 7-Day Free Trial

Syntara Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Syntara Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Syntara Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Syntara's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.syntaratx.com.au

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.